Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients
William J. Sandborn(University of San Diego), P. Rutgeerts, Bruce E. Sands(Icahn School of Medicine at Mount Sinai), G. R. Lichenstein(Western University), A. Olson, Brian G. Feagan(Western University), Daniel Rachmilewitz(Hadassah Academic College), D. Present(Western University), Willem J.S. de Villiers(Stellenbosch University), Suzanne Travers, Walter Reinisch(Medical University of Vienna), Stephen B. Hanauer(Northwestern University), Jewel Johanns(Johnson & Johnson (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital)
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k